Should we be PROactive in prescribing thiazolidinediones?

Pharmacy in Practice

Volumn 16, Issue 8, 2006, Pages 218-221

  Williams, Roger ^a  

^a MORRISTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLITAZONE DERIVATIVE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; STATINE DERIVATIVE; SULFONYLUREA;

ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG SAFETY; DYSLIPIDEMIA; FLUID RETENTION; GLUCOSE TOLERANCE; HEART FAILURE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; REVIEW;

EID: 33845427431     PISSN: 13581538     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Resven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595-607.
2. HPS Collaborative group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 5953 people with diabetes: a randomised placebo trial. Lancet 2003; 361: 2005-16.
3. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1988; 317: 703-13.
4. Burrill P. We must reassess our priorities and targets in type 2 diabetes. Pharmacy in practice 2006; 16(3): 72-8.
5. Shaughnessy AF, Slawson DC. What happened to the valid POEM's? A survey of review articles on the treatment of type 2 diabetes. BMJ 2003; 327: 266-71.
6. Alberti KG et al. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-62.
7. Summary of Product Characteristics. Piogitazone. Accessed from www.medicines.org.uk on 17/07/06.
8. Summary of Product Characteristics. Rosiglitazone. Accessed from www.medicines.org.uk on 17/7/06.
9. National Institute for health and Clinical Excellence. Glitazones in the treatment of type 2 diabetes. Technology appraisal guidance 63. August 2003. Accessed from www.nice.org.uk on 17/07/06.
10. The Medicines and Healthcare products Regulatory Authority and Commission on Human Medicines. Current problems in Pharmacovigilance. Oct. 2004; 30: 8.
11. Home PD et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD). Study design and protocol. Diabetologia 2005; 48: 1726-35.
12. Dormandy JA et al for the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
13. Freemantle N. How well does the evidence on pioglitazone back up researchers claims for a reduction in macrovascular events? BMJ 2005; 331: 836-8.
14. Lautamaki R et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. A 16-week randomised, double blind, placebo-controlled study. Diabetes 2005; 54: 2787-94.